Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition
AHA 2017 - Anaheim, CA3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events, irrespective of previous MI/stroke.
This 3-minute education provides a summary of just presented scientific data, recorded during the AHA 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
- Our reporting is based on the information provided at the AHA 2017 congress -